#USA #South San Francisco #Mahzi Therapeutics #Pitt Hopkins Syndrome #MZ-1866

Mahzi Therapeutics Takes a Major Step in Gene Therapy for Pitt Hopkins Syndrome

Mahzi Therapeutics, a pioneering biotechnology firm focusing on precision therapies for neurogenetic disorders, has recently achieved a crucial milestone by dosing its first patient in the Phase 1/2 UNITE study. This trial evaluates MZ-1866, an investigational gene therapy specifically designed to treat Pitt Hopkins Syndrome, a rare genetic condition affecting approximately 1 in 34,000 to 41,000 individuals.

Understanding Pitt Hopkins Syndrome

Pitt Hopkins Syndrome (PTHS) is the result of mutations in the TCF4 gene and manifests through a range of severe symptoms including autism, developmental delays, hypotonia, and various gastrointestinal complications. Currently, it is estimated that around 8,000 individuals in the United States live with this condition. A significant challenge for these patients and their families is the lack of effective treatments, leading to a considerable unmet medical need.

The Role of MZ-1866 in Treatment

MZ-1866 seeks to address the root cause of PTHS by delivering functional copies of the TCF4 gene. This novel AAV9-TCF4 gene replacement therapy has been developed with the support of the Muotri Lab at the University of California San Diego and is expected to tackle the fundamental biological issues patients face. Dr. Yael Weiss, CEO of Mahzi Therapeutics, stated that dosing the first patient marks a significant progression in their endeavors as a clinical-stage company dedicated to combating such conditions.

The Excitement in the Community

Audrey Davidow, President of the Pitt Hopkins Research Foundation, echoed this sentiment, highlighting the trial as a monumental moment for the community. For many families who have endured years of waiting for effective therapies, this trial represents a beacon of hope. The initiative reflects extensive advocacy and collaboration efforts aiming to pave the way for improved care for PTHS patients.

Details of the Phase 1/2 UNITE Study

The UNITE study is a multicenter, open-label trial set to evaluate the safety and preliminary efficacy of a single dose of MZ-1866 administered via intracerebroventricular delivery. The study aims to enroll approximately 12 participants across five locations, including the United States, Israel, and Spain. Besides safety, the study will assess exploratory endpoints for developmental, communication, cognitive, and motor functions.

This program not only symbolizes hope for patients but also represents a leap forward in the field of gene therapy, potentially changing the future landscape of care for those affected by rare genetic disorders.

Collaboration and Support

The realization of this study was bolstered by funding from the California Institute for Regenerative Medicine (CIRM), which aims to accelerate stem cell and gene therapy research to address pressing medical needs. CIRM has committed substantial funding to bolster research and development in this vital area.

Mahzi Therapeutics’ Mission

Mahzi Therapeutics remains dedicated to innovating precision therapies that can significantly improve outcomes for patients with neurogenetic conditions. The commencement of the MZ-1866 trial is a leap forward in their mission to collaborate with patient organizations and researchers in pursuit of effective treatments. The future is promising as they continue to strive for breakthroughs that can transform the lives of those enduring Pitt Hopkins Syndrome and similar disorders.

For more details about the study, visit ClinicalTrials.gov.

Stay tuned as Mahzi Therapeutics advances its groundbreaking research, an endeavor that holds the potential to reshape the medical landscape for rare genetic disorders.